Last reviewed · How we verify
NCT05466981
HCV-Smoking Cessation Study
NA trial testing Cognitive Behavioral Counseling in Hepatitis C in 10 participants. Completed in 11 November 2021.
11 November 2021
Quick facts
| Lead sponsor | Prisma Health-Upstate |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 23 November 2020 |
| Primary completion | 11 November 2021 |
| Estimated completion | 11 November 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cognitive Behavioral Counseling
Conditions studied
- Hepatitis C — all drugs for Hepatitis C →
- Smoking Cessation — all drugs for Smoking Cessation →
Sponsor
Prisma Health-Upstate — full company profile →
Who can join
18 and older, any sex, with Hepatitis C or Smoking Cessation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A 12-week study for patients who are being treated for Hepatitis C and would like to quit smoking. During the 12 weeks of Hepatitis C treatment, the research team will have counseling sessions with the participants to discuss challenges related to Hepatitis C and smoking.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05466981
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatitis C
Currently open trials in the same condition.
- NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
- NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
- NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
- NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
- NCT05208697 — Tele-Harm Reduction · NA · active not recruiting
Other Prisma Health-Upstate trials
Trials by the same sponsor.
- NCT07202039 — Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine · NA · not yet recruiting
- NCT07375212 — VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure · Phase 4 · withdrawn
- NCT07102615 — Intracervical Vasopressin · Phase 4 · recruiting
- NCT07101250 — Preoperative Acetazolamide · Phase 4 · recruiting
- NCT06874413 — Targeted Prehabilitation With Physical Exercise and Inspiratory Muscle Training for Elderly Frail Patients Prior to Vent · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05466981 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prisma Health-Upstate
- Last refreshed: 20 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05466981.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing